Menzies, Alexander M.
Amaria, Rodabe N. http://orcid.org/0000-0001-6876-278X
Rozeman, Elisa A.
Huang, Alexander C. http://orcid.org/0000-0002-0099-0492
Tetzlaff, Michael T.
van de Wiel, Bart A.
Lo, Serigne http://orcid.org/0000-0001-5092-5544
Tarhini, Ahmad A.
Burton, Elizabeth M.
Pennington, Thomas E.
Saw, Robyn P. M. http://orcid.org/0000-0002-3354-806X
Xu, Xiaowei
Karakousis, Giorgos C.
Ascierto, Paolo A. http://orcid.org/0000-0002-8322-475X
Spillane, Andrew J. http://orcid.org/0000-0002-9520-0181
van Akkooi, Alexander C. J.
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Mitchell, Tara C. http://orcid.org/0000-0002-8186-7284
Tawbi, Hussein A. http://orcid.org/0000-0003-1942-851X
Scolyer, Richard A. http://orcid.org/0000-0002-8991-0013
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
Blank, Christian U. http://orcid.org/0000-0002-7945-5846
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Article History
Received: 24 June 2020
Accepted: 20 November 2020
First Online: 8 February 2021
Competing interests
: A.M.M.—advisory board: BMS, MSD, Novartis, Roche and Pierre-Fabre. R.N.A.—research funding from Merck, BMS, Novartis and Iovance; consultant to Nektar and Iovance. E.A.R.—travel support from NanoString and MSD. R.A.S. has received fees for professional services from Merck Sharp & Dohme, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, Myriad, NeraCare and Amgen. H.A.T.—advisory board: BMS, Merck, Novartis, Roche and Array; research support to institution: BMS, Merck, Roche, Celgene and GSK. R.P.M.S.—advisory board: MSD and Novartis, and speaking honoraria: BMS. T.C.M.—advisory board: Merck, BMS and Array. A.v.A.—advisory boards/consultancy honoraria: Amgen, BMS, Novartis, MSD-Merck, Merck-Pfizer, Sanofi and 4SC, all paid to institute and unrelated to present work; research grants: Amgen, BMS and Novartis, all paid to institute and unrelated to present work. M.A.D.—advisory board member/consultant for BMS, Novartis, Array, Roche/Genentech, GSK and Sanofi-Aventis; principal investigator of research grant to institution from AstraZeneca, Roche/Genentech, GSK, Myriad, Oncothyreon and Sanofi-Aventis. C.U.B.—advisory role: BMS, MSD, Roche, Novartis, GSK, AstraZeneca, Pfizer, Lilly, GenMab, Pierre Fabre and Third Rock Ventures; research funding: BMS, Novartis and NanoString; stockownership: Uniti Cars. G.V.L.—consultant advisor to Aduro, Amgen, Array, BMS, MSD, Novartis, Roche, Pierre-Fabre and Sandoz. P.A.A.—consultant/advisory to Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar and Boehringer-Ingelheim; research funding from Bristol Myers-Squibb, Roche-Genentech and Array; travel support from MSD. J.A.W. is an inventor on a US patent application (PCT/US17/53.717) submitted by the University of Texas MD Anderson Cancer Center that covers methods to enhance immune checkpoint blockade responses by modulating the microbiome and on a patent Targeting B Cells To Enhance Response To Immune Checkpoint Blockade UTSC.P1412US.P1 - MDA19-023. J.A.W. reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune and Bristol-Myers Squibb. J.A.W. serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, and Ella Therapeutics. The authors have no additional competing interests.